Gesellschaft Fur Biotechnologische Forschung Mbh

Ciba-Geigy Corporation

Helmholtz-Zentrum Fuer Infektionsforschung Gmbh

Gesellschaft Fur Biotechnologische Forschung Gmbh

Helmholtz-Zentrum Fur Infektionsforschung Gmbh

Twincore, Zentrum Fur Experimentelle Und Klinische Infektionsforschung Gmbh

Brigitte Kunze

Herbert Irschik

Heinrich Steinmetz

Rolf Jansen

Klaus Gerth

Hans Reichenbach

Norbert Bedorf

Wolfram Trowitzsch-Kienast

Gerhard Hofle

Johannes P Pachlatko

Florenz Sasse

Edgar Forche

Hermann Augustiniak

Victor Wray

Dietmar Schomburg

Thomas Pietschmann

Gerhard H Ofle

Dietmar Schummer

Irene Wagner-Döbler

Juliane Gentzsch

The invention provides a compound termed Carolacton having the structure and derivatives thereof for medical use against biofilm formation by bacteria. 

Pharmaceutical composition effective against biofilms

The invention provides novel Thuggacin-Type macrolide compounds which form rearrangement products forming a lacton bond to different carbon atoms. The novel compounds can be produced by fermentation ofandand can be isolated by adsorption and chromoatograhic processing steps. The compounds are found to have antibiotic activity. The invention also relates to Thuggacin A, Thuggacin B, Thuggacin C, 13-Methyl-Thuggacin A, Thuggacin CMC-A, Thuggacin CMC-B and Thuggacin CMC-C AS Antimycobacterial Agents.

Macrolide antibiotics and their use for medical purposes

The invention relates to compounds of the following general formula I ##STR1## especially the compound of formula Ia referred to as thiangazole ##STR2## their pharmaceutically acceptable acid addition salts, processes for their preparation and therapeutic compositions and compositions that can be used in crop-protection.

Thiangazole, its preparation, compositions and use thereof

The invention relates to cyclic antibiotics of formula ##STR1## wherein the prefix R represents that the substituents on the adjacent carbon atom are in the R configuration; the prefix S represents that the substituents on the adjacent carbon atom are in the S configuration;

Macrocyclic antibodies

The invention relates to novel polycyclic alkaloids of formula ##STR1## in which R.sup.1 represents hydrogen or hydroxy, R.sup.2 represents hydrogen or acyl and A and B, independently of one another, each represents C.dbd.O or C--OH, and wherein the dashed line represents a C.dbd.C double bond at the position of the middle bond when A or B represents C.dbd.O, or at the position of the two outer bonds when A or B represents C--OH, a process for the manufacture of these compounds by fermentation of a novel microorganism of the species Myxococcus xanthus, the novel microorganism itself, pharmacetical preparations that contain the novel compounds, and the use of the novel compounds as antibiotics and as tumour-inhibiting agents and for the manufacture of pharmaceutical preparations.

Antibiotics from myxococcus

The invention relates to cyclic antibiotics of formula ##STR1## wherein the prefix R represents that the substituents on the adjacent carbon atom are in the R configuration; the prefix S represents that the substituents on the adjacent carbon atom are in the S configuration; R.sub.1 is hydrogen or hydroxy and R.sub.2 is hydroxy or .beta.-glucopyranosyloxy, and to the hydrates and salts thereof, especially pharmaceutically acceptable salts. The compounds of formula I are prepared by fermentation using the strain So ce 12 (NCIB 12134) of the species Sorangium celulosum and are effective antiobiotics.

Macrocyclic antibiotics

Growing community of inventors

Braunschweig, Germany

Brigitte Kunze